Influence of somatostatin receptor scintigraphy and CT/MRI on the clinical management of patients with gastrointestinal neuroendocrine tumors: An analysis in 188 patients

Digestion

Volumn 68, Issue 2-3, 2003, Pages 80-85

  Gotthardt, Martin ^a   Dirkmorfeld, Larissa M ^a   Wied, Matthias U ^a   Rinke, Anja ^a   Béhé, Martin P ^a   Schlieck, Anja ^a   Höffken, Helmut ^a   Alfke, Heiko ^a   Joseph, Klaus ^a   Klose, Klaus J ^a   Behr, Thomas M ^a   Arnold, Rudolph ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Computed tomography; Magnetic resonance imaging; Neuroendocrine tumors, management; Somatostatin receptor scintigraphy

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; IOPAMIDOL; PENTETREOTIDE; PENTETREOTIDE IN 111;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; GASTRINOMA; GASTROINTESTINAL TUMOR; GLUCAGONOMA; HUMAN; INSULINOMA; INTERMETHOD COMPARISON; LIVER METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY TUMOR; PRIORITY JOURNAL; RECURRENT CANCER; SCINTIGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; VIPOMA;

CROSS-OVER STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDIUM RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; NEUROENDOCRINE TUMORS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 9144227433     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074519     Document Type: Article

References (9)

1. Ricke J, Klose KJ, Mignon M, Öberg K, Wiedenmann B: Standardisation of imaging in neuroendocrine tumours: Results of a European delphi process. Eur J Radiol 2001;37:8-17.
2. Ricke J, Klose KJ: Imaging procedures in neuroendocrine tumours. Digestion 2000;62(suppl 1):39-44.
3. Kwekkeboom DJ, Krenning EP: Somatostatin receptor imaging. Semin Nucl Med 2002;32: 84-91.
4. Kwekkeboom DJ, Lamberts SW, Habbema JD, Krenning EP: Cost-effectiveness analysis of somatostatin receptor scintigraphy. J Nucl Med 1996;37:886-892.
5. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, Sutliff VE, Jensen RT: Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997;112:335-347.
6. Jamar F, Fiasse R, Leners N, Pauwels S: Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: Safety, efficacy and impact on patient management. J Nucl Med 1995; 36:542-549.
7. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, le Guludec D: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853-858.
8. Gibril F, Reynolds JC, Chen CC, Yu F, Göbel SU, Serrano J, Doppman JL, Jensen RT: Specificity of somatostatin receptor scintigraphy: A prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med 1999;40:554-555.
9. Williams ED, Sandler M: The classification of carcinoid tumours. Lancet 1963;i:238-239.